Malignant News and Research

RSS

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.

27 Nov 2014

Researchers reveal how cancer cells succeed at entrapping genetic program of growth inhibition

Healthy cells reduce their growth when there is a lack of oxygen (hypoxia). This makes it even more surprising that hypoxia is a characteristic feature of malignant tumours. In two publications in the current edition of the "Nature Communications" journal, researchers from Goethe University and Justus-Liebig-University of Giessen report on how cancer cells succeed at circumventing the genetic program of growth inhibition.

25 Nov 2014

20th annual edition of NCCN Guidelines for Prostate Cancer published

The National Comprehensive Cancer Network has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer—one of the eight original NCCN Guidelines published in November 1996.

23 Nov 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

UNC researchers develop new approach to block KRAS oncogene

Researchers from the UNC School of Medicine and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer.

14 Nov 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

University of Leeds researchers make new synthetic anti-cancer molecule

Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body.

13 Nov 2014

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

For patients with aggressive types of leukemia and other blood cancers, quickly identifying and starting the right treatment can make all the difference.

13 Nov 2014

Research finding could lead to new therapies for preventing growth of plexiform neurofibromas

UT Southwestern Medical Center researchers have determined the specific type of cell that gives rise to large, disfiguring tumors called plexiform neurofibromas, a finding that could lead to new therapies for preventing growth of these tumors.

11 Nov 2014

High-absorption BCM-95 Curcumin can reduce spread of cancer cells

A recently published cellular study on colorectal cancer showed that high-absorption BCM-95 Curcumin is able to reduce the spread of cancer cells and potentially increase the effectiveness of chemotherapy in the treatment of advanced colon cancer.

11 Nov 2014

M2Gen, Moffitt to serve as Central Laboratory and Biorepository for The National MDS Study

Moffitt Cancer Center and M2Gen have been awarded a contract from the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study (The National MDS Study).

6 Nov 2014

New device facilitates diagnosis of prostate cancer

Distinguishing between benign and malignant prostate tissue is difficult. A new device facilitates the diagnosis for doctors: Through a visual analysis, they can reliably determine if they are dealing with carcinoma within a minute-and-a-half. Fraunhofer researchers will be presenting the prototype at the COMPAMED trade fair in Düsseldorf from November 12th to 14th.

5 Nov 2014

Seno Imagio breast imaging system and associated predictive model can help eliminate breast biopsies

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced that the use of the Seno Imagio breast imaging system and the associated predictive model appear to have the potential to significantly improve the physicians’ ability to accurately rule out breast cancer compared to traditional ultrasound alone.

4 Nov 2014

Researchers identify potential therapeutic target for glioblastoma

A multicenter team of researchers has identified an enzyme key to the survival and spread of glioblastoma cancer cells that is not present in healthy brain cells, making the enzyme a promising therapeutic target.

4 Nov 2014

Moffitt researcher uncovers new approach to treat cancer

The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.

31 Oct 2014

Reduced chemotherapy exposure after surgery could decrease overall complications

A study of pediatric patients with hepatoblastoma led by researchers at Children's Hospital Los Angeles (CHLA) suggests an opportunity to reduce chemotherapy in up to 65 percent of patients, which could lead to a decrease in the incidence of adverse effects.